Granulocyte colony-stimulating factor in allogeneic bone marrow transplantation

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Allogeneic bone marrow transplantation (BMT) is a critical treatment for hematologic malignancies.
• Leukopenia and neutropenia following BMT increase infection risk and prolong recovery.
• Granulocyte colony-stimulating factor (G-CSF) is a cytokine that stimulates neutrophil production.

Purpose of the Study:

• To evaluate the efficacy and safety of recombinant G-CSF in accelerating leukocyte and neutrophil recovery post-allogeneic BMT.
• To compare G-CSF treatment with monocyte-CSF (M-CSF) and no CSF administration.

Main Methods:

• A Phase II clinical trial was conducted.
• Patients received either G-CSF, M-CSF, or no CSF after allogeneic BMT.
• Leukocyte and neutrophil counts, duration of leukopenia, febrile days, graft-versus-host disease incidence, and survival were monitored.

Main Results:

• G-CSF significantly shortened the time to achieve WBC counts >1,000/microliter and neutrophil counts >500/microliter.
• The G-CSF group experienced fewer febrile days compared to control groups.
• Graft-versus-host disease incidence and side effects (mild bone pain) were comparable or tolerable.
• Six of eight patients in the G-CSF group survived >5 months with high Karnofsky scores; no relapses were observed.

Conclusions:

• Recombinant G-CSF is well-tolerated and effectively accelerates myeloid recovery after allogeneic BMT.
• G-CSF demonstrated a promising reduction in complications like febrile days and potentially improved survival.
• Further long-term studies are warranted to confirm G-CSF's definitive impact on myeloid leukemia outcomes post-BMT.